We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment and Response |

Is 81-mg Aspirin Associated With Age-Related Macular Degeneration Risk?

David L. Keller, MD1
[+] Author Affiliations
1Providence Medical Group, Torrance, California
JAMA Intern Med. 2013;173(15):1476. doi:10.1001/jamainternmed.2013.8147.
Text Size: A A A
Published online


To the Editor It is unfortunate that the study by Liew and colleagues1 did not quantify the actual milligram dose of aspirin that was taken by each subject, but rather only the amount of time each subject took aspirin at any dose. The authors stated that aspirin is usually prescribed at a dose of 150 mg/d in Australia, which is an odd dose in that it is probably too small for effective analgesia in most patients, but larger than the minimum dose required for steady-state inhibition of platelet aggregation to reduce cardiovascular thrombosis.2 The “dose-response effect” that the authors found refers to the “time dose” or cumulative amount of time the patient took aspirin (at any milligram dose). It would be useful to know in addition whether there is a milligram dose-response effect for risks associated with daily aspirin use. Such an effect might be continuous or a “threshold effect,” such that aspirin below a certain dose, taken daily, might have no adverse effect. Most aspirin prescriptions in the United States are written for the lowest dose available, 81 mg, and are prescribed for the purpose of platelet inhibition, not analgesia.3 The physicians who write these prescriptions would be more interested in knowing whether an aspirin dose of 81 mg/d is associated with increased risk of age-related macular degeneration, rather than the less-commonly prescribed dose of 150 mg.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview





August 12, 2013
Jie Jin Wang, MMed, PhD; Gerald Liew, MBBS, PhD; Paul Mitchell, MD, PhD
1Centre for Vision Research, Department of Ophthalmology and Westmead Millennium Institute, University of Sydney, Sydney, Australia2Centre for Eye Research Australia, University of Melbourne, Melbourne, Australia
1Centre for Vision Research, Department of Ophthalmology and Westmead Millennium Institute, University of Sydney, Sydney, Australia
JAMA Intern Med. 2013;173(15):1476-1477. doi:10.1001/jamainternmed.2013.8131.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Related Collections